Large cohort studies have shown an increase in the rate of infection in patients on anti-TNF therapy when compared to DMARDs alone [2,3], particularly within the first six months of treatment, but this has not been replicated in all randomised controlled studies and observational cohort studies [4]. The gene discussed is TNF; the disease is infection.